American Association for Cancer Research
- AbstractDedifferentiated liposarcoma (DDLPS) is a rare cancer defined by amplification of mouse double minute 2 (MDM2) and cyclin-dependent kinase (CDK) 4. Conventional chemotherapy (doxorubicin) and targeted inhibition of MDM2 and CDK4 show sporadic responses, but most tumors display primary resistance. In this study, we used an unbiased approach to identify therapeutic strategies sensitizing to these […]
- The editors are publishing this note to alert readers to an issue about this article (1). In Fig. 1B, the image representing ERK-1/ERK-2 expression in UM-CLL was duplicated from the image representing ERK-1/ERK-2 expression in M-CLL. The authors located the original image for UM-CLL and provided a revised Fig. 1, which is included as an […]
- The editors are publishing this note to alert readers to issues about this article (1). Following an investigation analysis performed by the US Department of Health and Human Services Office of Research Integrity (2), and a subsequent review by the editors of Cancer Research, it was determined that:The image representing ΔNp63α expression in Fig. 1C […]
- AbstractChimeric antigen receptor T (CAR T)-cell therapy is revolutionizing cancer treatment in hematologic malignancies, but challenges related to the tumor microenvironment have hindered CAR T success, especially in solid tumors. Myeloid cells in particular have been implicated in CAR T efficacy. In this review, we discuss the roles of myeloid cells in CAR T–associated toxicities, […]
- The COVID-19 pandemic has highlighted the long-term impact of viral infections on health, yet the impact of SARS-CoV-2 infection on lung cancer development has remained unclear. In a recent study published in Cell, Qian and colleagues describe an increased risk for the development of lung cancer in patients who suffered from past severe COVID-19. To […]
- AbstractPurpose:The role of tumor-infiltrating lymphocytes (TIL) remains unclear in hormone receptor (HR)–positive/HER2-negative breast cancer, particularly in young patients, whose immune microenvironment could be altered by age-related host and tumor differences.Experimental Design:Patients with stage I to III HR-positive/HER2-negative tumors were identified from a prospective cohort study of patients with breast cancer diagnosed at age ≤40 years. […]
- AbstractPurpose:Human epidermal growth factor receptor 2 (HER2) overexpression occurs in various subtypes of salivary gland cancers (SGC) and can be associated with treatment challenges and poor clinical outcomes. Zanidatamab is a dual HER2-targeted, bispecific antibody that has demonstrated antitumor activity across multiple HER2-positive tumor types. This combined analysis aimed to assess the efficacy and safety […]
- AbstractPurpose:To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT).Patients and Methods:In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover […]
- SummaryEribulin was evaluated in angiosarcoma and epithelioid hemangioendothelioma (EHE) through two prospective international trials. Although encouraging activity was observed in EHE, its role in angiosarcoma may depend on further refinement through subgroup selection. These findings underscore the importance of histology-specific interpretation, innovative endpoints, and coordinated strategies for ultrarare sarcoma drug development.See related article by Cote […]
- AbstractPurpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis.Experimental Design:This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable […]
Cancer.gov
- A series of tissue changes may be associated with an increased risk of developing aggressive breast cancer among women with benign breast disease, and poorer rates of survival among women with invasive breast cancer.
- From 2010 through 2019, the incidence of 14 cancer types rose among people under age 50. However, the incidence of 19 other cancer types has decreased among this population.
- Overall death rates from cancer declined steadily among men and women from 2001 through 2022, even during the first two years of the COVID-19 pandemic, according to the 2024 Annual Report to the Nation on the Status of Cancer.
- A new form of personalized cancer immunotherapy, known as tumor infiltrating lymphocyte (TIL) therapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers.
- A study of 85,000 older adults in the U.K. suggests that light- and moderate-to-vigorous-intensity daily physical activity can reduce cancer risk. The number of steps taken daily may be more important for cancer risk than the intensity of activity, the study shows.
JAMA Oncology – Current Issue
- We sincerely thank the 740 peer reviewers who completed manuscript reviews for JAMA Oncology in 2025.
- This Viewpoint discusses increasing the transparency in cancer randomized clinical trials through the use of data and safety monitoring boards.
- This essay discusses the author’s reflection on his third cancer diagnosis and how he has lived with cancer throughout his life.
- JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.
- This cohort study assesses whether a tiered, evidence-based framework for matching genomic biomarkers to therapies is associated with differential overall survival in patients with advanced solid tumors.
ClinicalTrials.gov – Cancer
- Conditions: Melanoma Stage IV Sponsors: Medical University of Graz Recruiting
- Conditions: Prostate Cancer Interventions: Drug: QLF4113 for injection Sponsors: Qilu Pharmaceutical Co., Ltd. Not yet recruiting
- Conditions: Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma Interventions: Radiation: Postoperative radiotherapy; Drug: Capecitabine or S-1 Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting
- Conditions: Visual Field Defect; Stroke; Hemianopia Homonymous; Quadrantanopia; Cortical Blindness; Visual Field Defect, Peripheral; Visual Field Loss; Traumatic Brain Injury; Brain Tumor Interventions: Behavioral: High-level perceptual learning-based training; Behavioral: Low-level perceptual learning-based training Sponsors: Georgetown University; American Heart Association Recruiting
- Conditions: Limited Stage Small-Cell Lung Cancer Interventions: Drug: Tarlatamab; Drug: Durvalumab Sponsors: PrECOG, LLC.; Amgen Not yet recruiting
STAT!Ref Evidence Alerts
- JAMA Netw Open. 2026 May 1;9(5):e2610815. doi: 10.1001/jamanetworkopen.2026.10815.
- Am J Cardiol. 2026 Apr 1;269:83-91. doi: 10.1016/j.amjcard.2026.03.068.
- J Clin Oncol. 2026 Apr 14:JCO2501137. doi: 10.1200/JCO-25-01137.
- J Clin Oncol. 2026 Apr 1:JCO2600235. doi: 10.1200/JCO-26-00235.
- J Clin Oncol. 2026 Mar 12:JCO2500570. doi: 10.1200/JCO-25-00570.
*For providers of Salinas Valley Health, if you need access to any particular article referred to in these news feeds, please email Library@SalinasValleyHealth.com